Grossamide

Research use only, not for human use.

Grossamide possesses potential anti-inflammatory effects, it also has potential anti-neuroinflammatory effects against lipopolysaccharide (LPS)-induced inflammatory response in BV2 microglia cells. Cis-Grossamide K exerts a particularly strong anti-melanogenic activity on the cells without high cell toxicity.

Grossamide possesses potential anti-inflammatory effects, it also has potential anti-neuroinflammatory effects against lipopolysaccharide (LPS)-induced inflammatory response in BV2 microglia cells. Cis-Grossamide K exerts a particularly strong anti-melanogenic activity on the cells without high cell toxicity.

Grossamide downregulates LPS-mediated production of inflammatory molecules.Grossamide (0-20 μM, 1 h) inhibits the mRNA levels of TNF-α and IL-6 in a dose-dependent manner, inhibits LPS-induced NF-κB activation, and inhibits LPS-induced TLR4 and MyD88 expression without cytotoxicity. RT-PCR Cell Line:BV-2 microglia cell Concentration:0, 10, 15, and 20 μM Incubation Time:1 h and co-cultured with LPS (100 ng/mL) for another 6 h Result:Inhibited the mRNA levels of TNF-α and IL-6 in a dose-dependent manner.Western Blot Analysis Cell Line:BV-2 microglia cell Concentration:0, 10, 15, and 20 μM Incubation Time:1 h followed by LPS (100 ng/mL) stimulation for 1 h or 24 h Result:Inhibited LPS-induced phosphorylation of IκBα and significantly reduced phosphorylation of NF-κB p65 levels. Dose-dependently decreased the expression of TLR4 and MyD88.Cell Viability Assay Cell Line:BV-2 microglia cell Concentration:0, 10, 15, and 20 μM Incubation Time:1 h and co-cultured in the absence or presence of 100 ng/ mL LPS for 24 hResult:Had no cytotoxicity.

——

——

Others

Other Targets

——

——

——

80510-06-1

624.69

C36H36N2O8

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years